Partner
Thilo Schroeder
Managing Partner, Nextech Invest
- Firm
- Nextech Invest
- Title
- Managing Partner
- Role
- Managing partner
- Known as
- Investor
Record updated 4 October 2026
About
Thilo Schroeder, Ph.D. has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality. Since 2012, Thilo has helped grow and shape Nextech as a leading oncology focused venture firm. Thilo is a board member of Revolution Medicines (NASDAQ: RVMD), Circle Pharma, Atavistik Bio, MOMA Therapeutics, Exo Therapeutics, Synnovation Therapeutics, Khartis Therapeutics and Zenith Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC), Silverback Therapeutics (NASDAQ: SBTX), Peloton Therapeutics (acquired by Merck ( NYSE: MRK )), PMV Pharma (NASDAQ: PMVP), Alterome Therapeutics and IDEAYA Bioscience (NASDAQ: IDYA). Past observer seats include Cargo Therapeutics (NASDAQ: CRGX) and Black Diamond Therapeutics (NASDAQ: BDTX). Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen (NASDAQ: AMGN)) while studying at Ecole Supérieure de Biotechnologie de St
Is this you? Remove my profile